Q3 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised down its Q3 2025 earnings per share estimate for Neurogene from ($1.14) to ($1.18), indicating a negative outlook for the biotech company's financial performance.
• Neurogene's consensus estimate for full-year earnings stands at ($4.27) per share, with projected losses increasing in subsequent years to ($4.61) EPS for FY2025 and ($5.97) EPS for FY2026.
• Despite recent struggles, Neurogene has received a “Moderate Buy” consensus rating from analysts, with a target price averaging around $46.17.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for shares of Neurogene in a research report issued to clients and investors on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($1.18) per share for the quarter, down from their prior estimate of ($1.14). The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene's Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.61) EPS and FY2026 earnings at ($5.97) EPS.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.10.

A number of other research analysts have also weighed in on NGNE. Craig Hallum began coverage on shares of Neurogene in a research note on Tuesday, June 17th. They issued a "buy" rating and a $50.00 price objective for the company. HC Wainwright reduced their price objective on shares of Neurogene from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Baird R W lowered shares of Neurogene from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Robert W. Baird lowered shares of Neurogene from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $38.00 to $24.00 in a research report on Friday, May 16th. Finally, BMO Capital Markets restated an "outperform" rating and set a $26.00 price target (up from $22.00) on shares of Neurogene in a research report on Thursday, June 12th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Neurogene presently has a consensus rating of "Moderate Buy" and an average target price of $46.17.

Neurogene Stock Performance

Neurogene stock traded down $0.5750 during mid-day trading on Thursday, reaching $19.8750. The company's stock had a trading volume of 40,303 shares, compared to its average volume of 229,175. Neurogene has a 12-month low of $6.88 and a 12-month high of $74.49. The company has a market capitalization of $283.62 million, a P/E ratio of -4.61 and a beta of 1.69. The firm's fifty day moving average price is $20.35 and its two-hundred day moving average price is $17.33.

Institutional Trading of Neurogene

A number of hedge funds have recently made changes to their positions in NGNE. Geode Capital Management LLC lifted its holdings in shares of Neurogene by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 234,625 shares of the company's stock worth $5,365,000 after acquiring an additional 14,026 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Neurogene by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company's stock worth $124,000 after acquiring an additional 1,397 shares during the last quarter. Barclays PLC lifted its holdings in shares of Neurogene by 18.0% during the 4th quarter. Barclays PLC now owns 17,533 shares of the company's stock worth $401,000 after acquiring an additional 2,674 shares during the last quarter. Mariner LLC bought a new stake in shares of Neurogene during the 4th quarter worth $239,000. Finally, XTX Topco Ltd bought a new stake in shares of Neurogene during the 4th quarter worth $349,000. 52.37% of the stock is owned by institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.